NCT07140640View on ClinicalTrials.gov

Effect of a 20% Reduction in Hyperbaric Bupivacaine Dose on High Spinal Block Incidence in Cesarean Delivery: A Risk-Stratified Randomized Controlled Trial.

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

333

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

March 15, 2026

Study Completion Date

March 30, 2026

Conditions
Cesarean Section Complications
Interventions
DRUG

Hyperbaric Bupivacaine HCl 0.5% 12.5 mg

1- Standard dose group: receiving the typical dose of hyperbaric bupivacaine (12.5 mg hyperbaric bupivacaine + 25 mcg fentanyl).

DRUG

Hyperbaric Bupivacaine HCl 0.5% 10 mg

2- Reduced dose group: receiving a20% reduced dose of hyperbaric bupivacaine (10 mg hyperbaric bupivacaine + 25 mcg fentanyl).

Trial Locations (1)

000

Aswan university, Aswān

All Listed Sponsors
lead

Aswan University

OTHER